Preclinical Alzheimer's Disease study: Obicetrapib
Official title Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
ClinicalTrials.gov ID: NCT07794670
What this study is testing
What is Obicetrapib 10 mg?
Obicetrapib 10 mg is an investigational medicine, taken by mouth once daily, being studied as a potential treatment for preclinical alzheimer's disease.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether Obicetrapib can change early signs of Alzheimer's in people who do not yet have symptoms.
- Who it's for
- You may be able to join if you are an adult who might be at risk for early Alzheimer's disease.
- What's involved
- You would take the study medicine and attend check‑ups to see how it works and if it is safe.
- Time commitment
- The study lasts several months and requires regular visits to the clinic.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 85
You may be able to join if
- participants with preclinical AD
You likely can't join if
- APOE genotype not meeting protocol-defined eligibility criteria
The study team makes the final eligibility decision.
Where it is enrolling
- Nashville, Tennessee, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Nashville, Tennessee, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.